Biosplice’s mission is to restore health by delivering first-in-class therapies that harness alternative splicing. Their scientific platform is based on biological discoveries that govern tissue specialization and enable selective elimination of harmful proteins using small molecules. Biosplice has uncovered insights enabling Wnt pathway modulation that have unlocked the broad therapeutic potential of alternative splicing by targeting the CLK/DYRK family kinases. These kinases govern the selection of tissue-speciﬁc and disease-selective RNA splice-sites, thus deﬁning them as targets for drug therapy. Selectively reprogramming cellular behavior could lead to the discovery of new, potentially curative therapies for certain diseases. Biosplice’s clinical pipeline is focused on osteoarthritis and oncology, with early-stage programs in neurology and other areas of significant unmet medical need. Biosplice has developed six different compounds with fourteen different indications currently being explored in either preclinical or clinical trials. Biosplice’s DYRK 1A targeting molecules in currently in preclinical in vitro studies for several indications including select blood cancers and molecularly defined solid tumors. DYRK 1A is Dual-specificity tyrosine phosphorylation-regulated kinase (DYRK), a family of proteins that are upregulated in certain cancers such as pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC).